Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 3/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31496754 | 0.98 | SMN1; SMN2 (0.46) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6684458 | 0.98 | SMN1; SMN2 (0.46) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL31496770 | 0.98 | SMN1; SMN2 (0.46) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL19410299 | 0.98 | HTR6 (0.42) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27482975 | 0.96 | SMN1; SMN2 (0.44) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| SCHEMBL24480878 | 0.92 | ALDH1A1 (0.39) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| SCHEMBL4443392 | 0.92 | HTR6 (0.47) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| SCHEMBL3996939 | 0.92 | HTR6 (0.47) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| Formamide SCHEMBL27742498 | 0.88 | SMN1; SMN2 (0.37) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 | |
| SCHEMBL13700882 | 0.86 | HTR6 (0.41) | HTR6SMN1; SMN2HPGDKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 830 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125353-A1 | METHOD OF PREPARATION OF ZAVEGEPANT, SYNTHESIS INTERMEDIATES OF ZAVEGEPANT AND METHODS OF PREPARATION THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-06-19 | — | — | WO | claimed |
| CN-117551081-A | New preparation method of migraine therapeutic drug | 北京康立生医药技术开发有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | claimed |
| CN-109575045-A | Thienopyrimidines, preparation method, Pharmaceutical composition and its application | 南京红云生物科技有限公司 | 2019-04-05 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-8771403-B2 | Method and system for capturing carbon dioxide and/or sulfur dioxide from gas stream | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-08 | — | — | US | claimed |
| CN-103221114-A | Method and system for capturing carbon dioxide and/or sulfur dioxide from gas streams | UNIV CALIFORNIA | 2013-07-24 | — | — | CN | claimed |
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | claimed |
| WO-2012030630-A1 | METHOD AND SYSTEM FOR CAPTURING CARBON DIOXIDE AND/OR SULFUR DIOXIDE FROM GAS STREAM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-08 | — | — | WO | claimed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | claimed |
| CN-101454286-A | Process for producing phenoxypyridine derivative | EISAI R&D MAN CO LTD (JP) | 2009-06-10 | — | — | CN | claimed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | claimed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | claimed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12545670-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-10 | — | — | US | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| EP-4157836-B1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | BEIJING PHYTOVENT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2025125353-A1 | METHOD OF PREPARATION OF ZAVEGEPANT, SYNTHESIS INTERMEDIATES OF ZAVEGEPANT AND METHODS OF PREPARATION THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-06-19 | — | — | WO | disclosed |
| CN-116444501-B | Quinazoline derivative, preparation method thereof, pharmaceutical composition and application | 河北康泰药业有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025068371-A1 | INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025061141-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES | 成都思倍博医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-119661422-A | Synthesis method of 1- (1-methylpiperidine-4-yl) piperazine tri-hydrochloride | 白银京宇新药业有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119306709-A | Synthesis method of compound containing oxo-pyrido alicyclic heterocycle or alicyclic structure and novel intermediate | 成都思倍博医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20250002485-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-01-02 | — | — | US | disclosed |
| EP-4477225-A1 | USE OF SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | Beijing Phytovent Pharmaceutical Technology Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| EP-4157837-B1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2024-12-18 | — | — | EP | disclosed |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| US-20240382475-A1 | Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-116535393-B | Quinazoline compound and preparation method, pharmaceutical composition and application thereof | 河北康泰药业有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-3891167-B1 | ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 | Organon R&D Finland Oy (FI) | 2024-11-13 | — | — | EP | disclosed |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024222889-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | 成都思倍博医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| CN-118359584-A | Dihydropyrazoles and their use | 中国药科大学 | 2024-07-19 | — | — | CN | disclosed |
| EP-3556758-B1 | 1,2-DIHYDRO-1,6-NAPHTHYRIDIN-2-ONE DERIVATIVES AS CDK4/6 INHIBITORS | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| CN-117940411-A | Quinazoline derivative, or preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11945812-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-04-02 | — | — | US | disclosed |
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024046223-A1 | INDAZOLE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | 熙源安健医药（上海）有限公司 | 2024-03-07 | — | — | WO | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-117624191-A | Indazole carboxamide derivatives, preparation method and application thereof | 熙源安健医药（上海）有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-15 | — | — | US | disclosed |
| CN-114630819-B | Benzamide derivative for preventing or treating cancer, method for preparing the same, and pharmaceutical composition comprising the same as active ingredient | 韩国化学研究院 | 2024-02-13 | — | — | CN | disclosed |
| CN-117551081-A | New preparation method of migraine therapeutic drug | 北京康立生医药技术开发有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023205892-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| CN-111566100-B | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-116764689-A | Method for stripping carbamate from ion exchange resin | 埃克-泰克股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-116621912-A | Derivatives based on sarsasapogenin structure and use of pharmaceutical compositions thereof | 北京清博汇能医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116535393-A | Quinazoline compound and preparation method, pharmaceutical composition and application thereof | 河北康泰药业有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116444501-A | Quinazoline derivative, preparation method thereof, pharmaceutical composition and application | 河北康泰药业有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023125486-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-06 | — | — | WO | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230181693-A1 | METHODS OF TREATING INFLAMMATORY SKIN DISORDERS | NEPSONE EHF (IS) | 2023-06-15 | — | — | US | disclosed |
| CN-116234806-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023083330-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 百极优棠(广东)医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-116034106-A | Cyclic 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-113150058-B | Tripterine derivative and preparation method and application thereof | 沈阳药科大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-4166553-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| EP-4157836-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157837-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2023030216-A1 | QUINAZOLINE DERIVATIVE, OR PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| CN-110950807-B | Biaryl compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-03-03 | — | — | CN | disclosed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-11517612-B2 | Methods of treating inflammatory skin disorders | NEPSONE EHF (IS) | 2022-12-06 | — | — | US | disclosed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| CN-113024454-B | Synthesis method of brigatinib intermediate | 浙江工业大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-114980862-A | Intranasal pharmaceutical compositions of CGRP inhibitors | 拜尔哈文制药股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022170164-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022165291-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-114630819-A | Benzamide derivatives for preventing or treating cancer, preparation method thereof, and pharmaceutical composition comprising the same as active ingredient | 韩国化学研究院 | 2022-06-14 | — | — | CN | disclosed |
| US-11351265-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-4005572-A1 | BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220041647-A1 | ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 | FORENDO PHARMA LTD. (FI) | 2022-02-10 | — | — | US | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| WO-2021238827-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-110041302-B | 2-amino-4-substituted pyridine derivative and synthesis method and application thereof | 南方医科大学 | 2021-11-30 | — | — | CN | disclosed |
| EP-3891167-A1 | ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 | Forendo Pharma Ltd (FI) | 2021-10-13 | — | — | EP | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-09-28 | — | — | US | disclosed |
| CN-113412269-A | Estra-1, 3,5(10) -trienes having a condensed pyrazole ring in position 16(17) as 17-HSD1 inhibitors | 佛恩多制药有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11081662-B2 | Photoelectric conversion element and solar cell | RICOH COMPANY, LTD. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210230149-A1 | ARYLNAPHTHALENE COMPOUNDS AS VACUOLAR-ATPASE INHIBITORS AND THE USE THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2021-07-29 | — | — | US | disclosed |
| CN-113150058-A | Tripterine derivative and preparation method and application thereof | 沈阳药科大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-113024454-A | Synthesis method of brigatinib intermediate | 浙江工业大学 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021127070-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127070-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| CN-112888438-A | Prodrugs of CGRP antagonists | 拜尔哈文制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-107709322-B | Tricyclic compounds as anticancer agents | 百时美施贵宝公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| CN-108707139-B | Aminopyrimidine compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2021-04-06 | — | — | CN | disclosed |
| WO-2021057882-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021023233-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2021-02-11 | — | — | WO | disclosed |
| US-10898891-B2 | Process for stripping carbamate from ion exchange resin | ECO-TEC LTD. (CA) | 2021-01-26 | — | — | US | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| WO-2020239123-A1 | AROMATIC HETEROCYCLIC DERIVATIVE MODULATOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239077-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020216371-A1 | EGFR INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20200280007-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL | TANAKA YUUJI (JP) | 2020-09-03 | — | — | US | disclosed |
| CN-111566100-A | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200223816-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| EP-3666268-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020115371-A1 | ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 | FORENDO PHARMA LTD (FI) | 2020-06-11 | — | — | WO | disclosed |
| US-10676474-B2 | 1,6-naphthyridine derivatives as CDK4/6 inhibitor | CSTONE PHARMACEUTICALS (KY) | 2020-06-09 | — | — | US | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| EP-3374407-B1 | FUNCTIONAL INITIATOR FOR ANIONIC POLYMERIZATION | BRIDGESTONE CORP (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-110950807-A | Biaryl compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-04-03 | — | — | CN | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-20200048217-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200031795-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |
| EP-3556758-A1 | CDK4/6 INHIBITOR | CSTONE PHARMACEUTICALS (KY) | 2019-10-23 | — | — | EP | disclosed |
| US-20190315745-A1 | CDK4/6 INHIBITOR | CSTONE PHARMACEUTICALS (KY) | 2019-10-17 | — | — | US | disclosed |
| WO-2019189781-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | 東レ株式会社 | 2019-10-03 | — | — | WO | disclosed |
| EP-3233071-B1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS LLC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| WO-2019165229-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-3294739-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-2906221-B1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RES INST (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| CN-109575045-A | Thienopyrimidines, preparation method, Pharmaceutical composition and its application | 南京红云生物科技有限公司 | 2019-04-05 | — | — | CN | disclosed |
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190009268-A1 | Process for Stripping Carbamate from Ion Exchange Resin | CERBERUS BUSINESS FINANCE AGENCY, LLC, AS COLLATERAL AGENT | 2019-01-10 | — | — | US | disclosed |
| US-10174024-B2 | 5H-pyrido[3,2-B]indole compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2018-07-26 | — | — | US | disclosed |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2018-07-26 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3337612-A1 | PROCESS FOR STRIPPING CARBAMATE FROM ION EXCHANGE RESIN | Eco-Tec Ltd. (CA) | 2018-06-27 | — | — | EP | disclosed |
| EP-3189060-B1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PF MEDICAMENT (FR) | 2018-06-20 | — | — | EP | disclosed |
| EP-3321268-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2018-05-16 | — | — | EP | disclosed |
| US-9969743-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3309148-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3307740-A1 | 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180093983-A1 | 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2018-04-05 | — | — | US | disclosed |
| EP-3294739-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-20170283397-A1 | SUBSTITUTED 1-H-INDOL-3-YL-BENZAMIDE AND 1, 1'-BIPHENYL ANALOGS AS HISTONE DEMETHYLASE INHIBITORS | UNIV UTAH RES FOUND (US) | 2017-10-05 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2831079-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2017-08-16 | — | — | EP | disclosed |
| US-9725449-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3189060-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017114500-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | 恩瑞生物医药科技（上海）有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-07-06 | — | — | US | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2017076355-A1 | PYRIMIDINE DERIVATIVE AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2017-05-11 | — | — | WO | disclosed |
| EP-2766346-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9598387-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017044792-A1 | ACETAMIDE THIENOTRIAZOLDIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170073330-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2017-02-23 | — | — | US | disclosed |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20160376240-A1 | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use | ABBVIE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2016-12-15 | — | — | US | disclosed |
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-3097091-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
| WO-2016183115-A1 | 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183118-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | WO | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160318904-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-03 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9447110-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-20 | — | — | US | disclosed |
| US-9434713-B2 | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-09-06 | — | — | US | disclosed |
| CN-104144915-B | Nitrogenous aromatic heterocyclic compounds | 安斯泰来制药有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9422264-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9403796-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-3044218-A2 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | Board Of Regents Of the University Of Texas System (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2016100542-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100546-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2016034634-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2015-12-10 | — | — | US | disclosed |
| US-9206159-B2 | Piperazine-piperidine compounds as hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2906221-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | Southern Research Institute (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015112445-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-07-16 | — | — | US | disclosed |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-07-16 | — | — | US | disclosed |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-07-16 | — | — | US | disclosed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015091532-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9023854-B2 | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-9000172-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2015028848-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS MULTI-KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2015-03-05 | — | — | WO | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-02-05 | — | — | US | disclosed |
| WO-2014206150-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-18 | — | — | US | disclosed |
| EP-2257591-B1 | FUNCTIONALIZED POLYMERS AND INITIATORS FOR MAKING SAME | BRIDGESTONE CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| CN-104144915-A | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC | 2014-11-12 | — | — | CN | disclosed |
| CN-102026995-B | 5, 6-disubstituted oxindole derivatives and their use | ABBOTT GMBH & CO.KG (DE) | 2014-10-29 | — | — | CN | disclosed |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2668177-B1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| CN-101952276-B | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO.KG (DE) | 2014-10-22 | — | — | CN | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20140296214-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | disclosed |
| CN-102388060-B | Actagardine derivatives | NOVACTA BIOSYSTEMS LTD | 2014-09-10 | — | — | CN | disclosed |
| US-8815868-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2114923-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2014-08-06 | — | — | EP | disclosed |
| CN-101981027-B | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | ABBOTT GMBH & CO KG | 2014-08-06 | — | — | CN | disclosed |
| CN-102834388-B | Cgrp receptor antagonist | BRISTOL MYERS SQUIBB CO | 2014-07-16 | — | — | CN | disclosed |
| US-20140194440-A1 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-10 | — | — | US | disclosed |
| US-8772305-B2 | Substituted pyridinyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-8771403-B2 | Method and system for capturing carbon dioxide and/or sulfur dioxide from gas stream | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-08 | — | — | US | disclosed |
| US-RE45003-E1 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-RE45003-E1 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8703775-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8703774-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | disclosed |
| WO-2014059265-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140024620-A1 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-2231644-B1 | 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBVIE DEUTSCHLAND (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2670765-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | Bristol-Myers Squibb Company (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130324725-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-05 | — | — | US | disclosed |
| EP-2668177-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| CN-103429607-A | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL MYERS SQUIBB CO | 2013-12-04 | — | — | CN | disclosed |
| US-8580842-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130287730-A1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-31 | — | — | US | disclosed |
| EP-2646819-A1 | ASSAYS AND BIOMARKERS FOR LRRK2 | Genentech, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
| US-8546401-B2 | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| CN-101611028-B | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO KG | 2013-09-11 | — | — | CN | disclosed |
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| CN-101535276-B | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC | 2013-08-28 | — | — | CN | disclosed |
| EP-2623504-A1 | 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | Abbott GmbH & Co. KG (DE) | 2013-08-07 | — | — | EP | disclosed |
| CN-103221114-A | Method and system for capturing carbon dioxide and/or sulfur dioxide from gas streams | UNIV CALIFORNIA | 2013-07-24 | — | — | CN | disclosed |
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8465947-B2 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-06-18 | — | — | US | disclosed |
| US-8465947-B2 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-06-18 | — | — | US | disclosed |
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20130139695-A1 | METHOD AND SYSTEM FOR CAPTURING CARBON DIOXIDE AND/OR SULFUR DIOXIDE FROM GAS STREAM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-06 | — | — | US | disclosed |
| US-8455507-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455507-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455507-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| CN-103087078-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| WO-2013056060-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | disclosed |
| CN-102015866-B | Functionalized polymers and initiators for making same | BRIDGESTONE CORP | 2013-04-17 | — | — | CN | disclosed |
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
| EP-2552906-A1 | CGRP RECEPTOR ANTAGONIST | Bristol-Myers Squibb Company (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| EP-2546252-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546251-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546250-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-8350055-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-01-08 | — | — | US | disclosed |
| EP-2114921-B1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO KG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8338590-B2 | Substituted oxindole derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120322809-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AbbVie Deutschland GmbH & Co. KG (DE) | 2012-12-20 | — | — | US | disclosed |
| CN-102834388-A | Cgrp receptor antagonist | BRISTOL MYERS SQUIBB CO | 2012-12-19 | — | — | CN | disclosed |
| EP-2231643-B1 | Amidomethyl-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBOTT GMBH & CO KG (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| EP-2231645-B1 | 5-Halogen-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBOTT GMBH & CO KG (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268828-B2 | Inhibitors of the chemokine receptor CxCR3 | SANOFI (FR) | 2012-09-18 | — | — | US | disclosed |
| WO-2012075046-A9 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-102639513-A | Sphingosine kinase inhibitors | MERCK PATENT GMBH | 2012-08-15 | — | — | CN | disclosed |
| WO-2012106190-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012101013-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-8227562-B2 | Functionalized polymers and initiators for making same | BRIDGESTONE CORPORATION (JP) | 2012-07-24 | — | — | US | disclosed |
| EP-2475643-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| CN-102516240-A | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-06-27 | — | — | CN | disclosed |
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| CN-101208334-B | Novel cyclic amines | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| WO-2012075046-A1 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-1979375-B9 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| CN-101198590-B | pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2012030630-A1 | METHOD AND SYSTEM FOR CAPTURING CARBON DIOXIDE AND/OR SULFUR DIOXIDE FROM GAS STREAM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120046270-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-8119805-B2 | Substituted disulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119805-B2 | Substituted disulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| CN-102341398-A | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH | 2012-02-01 | — | — | CN | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| CN-1910166-B | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-01-04 | — | — | CN | disclosed |
| US-20110318393-A1 | Substituted Pyrazole Compounds | MIIKANA THERAPEUTICS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306091-A1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110306091-A1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2393803-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-1979375-B1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LTD (GB) | 2011-11-23 | — | — | EP | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | disclosed |
| CN-102227219-A | Substituted pyrazole compounds | MIKANA THERAPEUTICS INC | 2011-10-26 | — | — | CN | disclosed |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO. KG (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2373313-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | Miikana Therapeutics, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121223-A1 | 6-(ALKYL- OR CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLE DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | WO | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2350003-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-7989416-B2 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989416-B2 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7985747-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| CN-101454286-B | Process for producing phenoxypyridine derivative | EISAI R&D MAN CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| CN-101124208-B | Novel heteroaryl acetamide | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-7951807-B2 | Substituted oxindol derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20110124658-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110092513-A1 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG | 2011-04-21 | — | — | US | disclosed |
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG | 2011-04-21 | — | — | US | disclosed |
| CN-102026995-A | 5, 6-disubstituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO KG | 2011-04-20 | — | — | CN | disclosed |
| CN-102015866-A | Functionalized polymers and initiators for making same | BRIDGESTONE CORP | 2011-04-13 | — | — | CN | disclosed |
| CN-102007108-A | Inhibitors of chemokine receptor CxCR3 | SANOFI AVENTIS | 2011-04-06 | — | — | CN | disclosed |
| US-20110077241-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110071156-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABOTT GMBH & CO KG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| WO-2011026959-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-7902379-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7897603-B2 | Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| CN-101981027-A | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | ABBOTT GMBH & CO KG | 2011-02-23 | — | — | CN | disclosed |
| CN-101965351-A | Benzofuran pyrimidinones | EXELIXIS INC | 2011-02-02 | — | — | CN | disclosed |
| CN-101952276-A | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO KG | 2011-01-19 | — | — | CN | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
| US-20110009583-A1 | FUNCTIONALIZED POLYMERS AND INITIATORS FOR MAKING SAME | BRIDGESTONE CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-2262784-A1 | INHIBITORS OF THE CHEMOKINE RECEPTOR CXCR3 | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7851636-B2 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-2257591-A2 | FUNCTIONALIZED POLYMERS AND INITIATORS FOR MAKING SAME | Bridgestone Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100305088-A1 | INHIBITORS OF THE CHEMOKINE RECEPTOR CxCR3 | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | US | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249114-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249114-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2231645-A2 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231644-A2 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231643-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234361-A1 | SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234361-A1 | SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010099938-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2010-09-10 | — | — | WO | disclosed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010094695-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | WO | disclosed |
| EP-1737842-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INT (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| WO-2010089084-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2010-08-12 | — | — | WO | disclosed |
| US-7767671-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2010062848-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIKANA THERAPEUTICS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2189472-A1 | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae | Novacta Biosystems Limited (GB) | 2010-05-26 | — | — | EP | disclosed |
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2010051977-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051977-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| CN-1764661-B | Benzenesulfonamide derivatives, process for their preparation and their use for the treatment of pain | FOURNIER LAB SA | 2010-05-05 | — | — | CN | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700598-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700598-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696196-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-2167465-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Boehringer Ingelheim International GmbH (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2010026262-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-20100048459-A1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048459-A1 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| EP-2155678-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC Neurosciences GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-7666901-B2 | -[(Diethylamino)methylene]-7,11-dihydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,10-dioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; antitumor, -carcinogenic, proliferative agents; imroved antitumor activity; nontoxic; TOR (target of rapamycin) inhibitors | WYETH (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009775-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2010-01-28 | — | — | WO | disclosed |
| EP-2146982-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-01-14 | — | — | US | disclosed |
| WO-2010001169-A2 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | WO | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| CN-101611028-A | The oxindole derivatives that replaces and they are used as the purposes of vasopressin receptor ligands | ABBOTT GMBH & CO KG (DE) | 2009-12-23 | — | — | CN | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2114923-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114921-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-1931341-B1 | 1H-INDOLE-PYRIDINECARBOXAMIDE AND 1H-INDOLE-PIPERIDINECARBOXAMIDE DERIVATIVES AND THEIR USE AS TYROSINE HYDROXYLASE INDUCERS | SERVIER LAB (FR) | 2009-11-04 | — | — | EP | disclosed |
| US-7612089-B2 | Tetrahydroisoquinolines as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | LES LABORATOIRES SERVIER (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2108648-A1 | Selected CGRP antagonists, method for their manufacture and use as medicines | Boehringer Ingelheim International GmbH (DE) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108648-A1 | Selected CGRP antagonists, method for their manufacture and use as medicines | Boehringer Ingelheim International GmbH (DE) | 2009-10-14 | — | — | EP | disclosed |
| CN-101553481-A | Substituted sulfonamide derivatives | GRUENENTHAL GMBH (DE) | 2009-10-07 | — | — | CN | disclosed |
| US-7598391-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2009-10-06 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| WO-2009117329-A2 | FUNCTIONALIZED POLYMERS AND INITIATORS FOR MAKING SAME | BRIDGESTONE CORPORATION (JP) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117329-A2 | FUNCTIONALIZED POLYMERS AND INITIATORS FOR MAKING SAME | BRIDGESTONE CORPORATION (JP) | 2009-09-24 | — | — | WO | disclosed |
| CN-101535276-A | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1732917-B8 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2009-09-09 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| WO-2009105435-A1 | INHIBITORS OF THE CHEMOKINE RECEPTOR CXCR3 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1732917-B1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1732917-B1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009077874-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R & D MANAGEMENT CO., LTD. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7547694-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| WO-2009071687-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071689-A2 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071690-A2 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2066659-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-06-10 | — | — | EP | disclosed |
| CN-101454286-A | Process for producing phenoxypyridine derivative | EISAI R&D MAN CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1606288-B1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | FOURNIER LAB SA (FR) | 2009-06-03 | — | — | EP | disclosed |
| EP-2061452-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | Piramal Life Sciences Limited (IN) | 2009-05-27 | — | — | EP | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20090111797-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111797-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| CN-101394853-A | Use of pyrazolo [1, 5-a ] pyrimidin-7-ylamine derivatives in the treatment of neurological disorders | NOVARTIS AG (CH) | 2009-03-25 | — | — | CN | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-2027106-A2 | CGRP RECEPTOR ANTAGONISTS | Vertex Pharmaceuticals Incorporated (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7491717-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-7491717-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-2016049-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | disclosed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | disclosed |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-1993552-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008125570-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128009-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| WO-2008107322-A1 | INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE DERIVATIVES INCLUDING A PIPERIDINE OR PIPERAZINE CORE AS ANTI-NEOPLASIC AGENTS OR CELL PROLIFERATION INHIBITORS | CEREP (FR) | 2008-09-12 | — | — | WO | disclosed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
| CN-101257905-A | Novel 1h-indole-pyridinecarboxamide derivatives and 1h-indole-piperidinecarboxamide and their use as hydroxalase tyrosine inducers | SERVIER LAB (FR) | 2008-09-03 | — | — | CN | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008080973-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080970-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008076883-A2 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| CN-101208334-A | Novel cyclic amines | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | disclosed |
| EP-1931341-A2 | NOVEL 1H-INDOLE-PYRIDINECARBOXAMIDE DERIVATIVES AND 1H-INDOLE-PIPERIDINECARBOXAMIDE AND THEIR USE AS HYDROXALASE TYROSINE INDUCERS | Les Laboratoires Servier (FR) | 2008-06-18 | — | — | EP | disclosed |
| CN-101198590-A | Novel pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD (JP) | 2008-06-11 | — | — | CN | disclosed |
| WO-2008065068-A2 | SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| EP-1846381-B1 | HETEROARYLACETAMIDES AS FACTOR Xa INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-7361672-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7358268-B2 | Imidazole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2008026125-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008024692-A1 | N-OXIDE ARYL SULFONES AND SULFOXIDES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| CN-101124208-A | Novel heteroaryl acetamide | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1409479-B1 | 1-GLYCINYL-4-(1-METHYLPIPERIDIN-4-YL)PIPERAZINES AND -PIPERIDINES AS FACTOR XA ANTAGONISTS | LILLY CO ELI (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| CN-101098873-A | 1, 4-substituted pyrazolopyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2008-01-02 | — | — | CN | disclosed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070275951-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | MUELLER STEPHAN G | 2007-11-29 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7297706-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1773814-B1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO KG (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007122219-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1846381-A2 | NOVEL HETEROARYLACETAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| CN-101039952-A | 17-Hydroxywortmannin analogs as PI3K inhibitors | WYETH CORP (US) | 2007-09-19 | — | — | CN | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |
| US-7265121-B2 | Chemical compounds | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| CN-101018778-A | Substituted oxindole derivatives and medicaments containing them | ABBOTT GMBH & CO KG (DE) | 2007-08-15 | — | — | CN | disclosed |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | AbbVie Deutschland GmbH & Co. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| EP-1812441-A1 | 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007083112-A2 | LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE | NOVACTA BIOSYSTEMS LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| EP-1373224-B1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1799699-A1 | ANALOGS OF 17-HYDROXYWORTMANNIN AS PI3K INHIBITORS | Wyeth (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1801106-A2 | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| CN-1976916-A | Selected CGRP-antagonists, method for the production thereof and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-06-06 | — | — | CN | disclosed |
| US-7214676-B2 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| EP-1773814-A2 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | Abbott GmbH & Co. KG (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2007036532-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | WILEY MICHAEL R | 2007-03-29 | — | — | US | disclosed |
| WO-2007025774-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025775-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| WO-2007025776-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049558-A1 | New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | PFIZER INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| CN-1910166-A | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| CN-1906167-A | Novel pyridine derivative and pyrimidine derivative (2) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906166-A | Novel pyridine derivative and pyrimidine derivative (1) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| US-7166606-B2 | Certain 1-(D-cycloproplyglycinyl)-4-piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor Xa | ELI LILLY AND COMPANY (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166606-B2 | Certain 1-(D-cycloproplyglycinyl)-4-piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor Xa | ELI LILLY AND COMPANY (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166606-B2 | Certain 1-(D-cycloproplyglycinyl)-4-piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor Xa | ELI LILLY AND COMPANY (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2007006922-A2 | NOVEL 1H-INDOLE-PYRIDINECARBOXAMIDE DERIVATIVES AND 1H-INDOLE-PIPERIDINECARBOXAMIDE AND THEIR USE AS HYDROXYLASE TYROSINE INDUCERS | LES LABORATOIRES SERVIER (FR) | 2007-01-18 | — | — | WO | disclosed |
| EP-1740577-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| EP-1732917-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-20 | — | — | EP | disclosed |
| CN-1288135-C | Certain 1- (D-cyclopropylglycyl) -4- (piperidin-4-yl) piperazine compounds as inhibitors of the serine protease factor XA | LILLY CO ELI (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| CN-1283638-C | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2006-11-08 | — | — | CN | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| CN-1856498-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB (US) | 2006-11-01 | — | — | CN | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-7115609-B2 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | ELI LILLY AND COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-7078415-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| WO-2006066778-A2 | NOVEL HETEROARYLACETAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | US | disclosed |
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | WYETH (US) | 2006-06-15 | — | — | US | disclosed |
| WO-2006063113-A2 | UREAS AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1667993-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | Abbott GmbH & Co. KG (DE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006055951-A2 | TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006050946-A1 | 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006044453-A1 | ANALOGS OF 17-HYDROXYWORTMANNIN AS PI3K INHIBITORS | WYETH (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| CN-1764651-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |
| CN-1764661-A | Benzenesulfonamide derivatives, process for their preparation and their use for the treatment of pain | FOURNIER LAB SA (FR) | 2006-04-26 | — | — | CN | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| US-7022696-B2 | Piperazino-derivatives and their use as PDE4 inhibitor | ALTANA PHARMA AG (DE) | 2006-04-04 | — | — | US | disclosed |
| WO-2006005609-A2 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO.KG (DE) | 2006-01-19 | — | — | WO | disclosed |
| EP-1606288-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| CN-1708492-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| CN-1708493-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005103037-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005092880-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| EP-1397348-B1 | FACTOR XA INHIBITOR | LILLY CO ELI (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2005082891-A1 | -QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1492767-B1 | CERTAIN 1-(D-CYCLOPROPYLGLYCINYL)-4-(PIPERIDIN-4-YL)PIPERAZINE COMPOUNDS AS INHIBITORS OF THE SERINE PROTEASE FACTOR XA | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| EP-1558600-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558601-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| CN-1213040-C | Serine protease inhibitors | LILLY CO ELI (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| CN-1642914-A | Certain 1- (D-cyclopropylglycyl) -4- (piperidin-4-yl) piperazine compounds as inhibitors of the serine protease factor XA | LILLY CO ELI (US) | 2005-07-20 | — | — | CN | disclosed |
| EP-1455787-B1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | LILLY CO ELI (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| CN-1203069-C | Substituted piperidines, medicaments containing these compounds, and methods for production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-05-25 | — | — | CN | disclosed |
| US-20050096328-A1 | Certain 1-(D-cycloproplyglycinyl)-4-piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa | ELI LILLY AND COMPANY | 2005-05-05 | — | — | US | disclosed |
| WO-2005030755-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2005-04-07 | — | — | WO | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| CN-1589270-A | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2005-03-02 | — | — | CN | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026928-A1 | Chemical compounds | ELI LILLY AND COMPANY | 2005-02-03 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| EP-1492767-A1 | CERTAIN 1-(D-CYCLOPROPYLGLYCINYL)-4-(PIPERIDIN-4-YL)PIPERAZINE COMPOUNDS AS INHIBITORS OF THE SERINE PROTEASE FACTOR XA | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | ELI LILLY AND COMPANY | 2004-12-16 | — | — | US | disclosed |
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20040214843-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
| EP-1456198-A1 | ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1455787-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040162295-A1 | Pharmaceutical compound | ELI LILLY AND COMPANY | 2004-08-19 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | ATLANTA PHARMA AG (DE) | 2004-07-08 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
| EP-1409479-A2 | 1-GLYCINYL-4-(1-METHYLPIPERIDIN-4-YL)PIPERAZINES AND -PIPERIDINES AS FACTOR XA ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6720317-B1 | 1-NAPHTH-2-YL-1H-PYRAZOLE-5-(4-AMIDINOPHENYL)CARBOXYAMIDE, MULTIPLY SUBSTITUTED; NON AMIDINO ANTICOAGULANTS; HEMOSTATIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| EP-1397348-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6686368-B1 | Inhibitors of factor Xa | MILLENNIUM PAHRMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1373224-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003084929-A1 | CERTAIN 1-(D-CYCLOPROPYLGLYCINYL)-4-(PIPERIDIN-4-YL)PIPERAZINE COMPOUNDS AS INHIBITORS OF THE SERINE PROTEASE FACTOR XA | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084929-A1 | CERTAIN 1-(D-CYCLOPROPYLGLYCINYL)-4-(PIPERIDIN-4-YL)PIPERAZINE COMPOUNDS AS INHIBITORS OF THE SERINE PROTEASE FACTOR XA | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| CN-1438999-A | Serine protease inhibitors | LILLY CO ELI (US) | 2003-08-27 | — | — | CN | disclosed |
| WO-2003050109-A1 | ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003049735-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| CN-1414960-A | Substituted piperidines, medicaments containing these compounds, and methods for production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-30 | — | — | CN | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1289972-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2003010160-A2 | 1-GLYCINYL-4 (METHYLPIPERIDIN-4-YL) PIPERAZINES AND -PIPERRIDINES AS FACTOR XA ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-06 | — | — | WO | disclosed |
| US-6506751-B1 | The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the preparation of the final products, pharmaceutical compositions containing the final products are also taught. invention is directed to | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| CN-1390206-A | Inhibitors of factor Xa | COR THERAPEUTICS INC (US) | 2003-01-08 | — | — | CN | disclosed |
| US-20020198198-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002100847-A2 | FACTOR XA INHIBITOR | ELI LILLY AND COMPANY (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002074754-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
| EP-1216231-A2 | INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
| WO-2001019798-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| CN-1183770-A | Piperazine derivatives, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1998-06-03 | — | — | CN | disclosed |
| WO-1996020173-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996020173-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | HTR6 103/4885SMN1; SMN2 4549/4885HPGD 195/4885 |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | HTR6 1142/4885SMN1; SMN2 1746/4885HPGD 1377/4885 |
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | ADORA1, P2RY1, P2RY11 | HTR6 290/4885SMN1; SMN2 3478/4885HPGD 643/4885 |
| US-20130287730-A1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ZC3HAV1, ITPA, HAVCR2 | HTR6 4070/4885SMN1; SMN2 4390/4885HPGD 1307/4885 |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | HTR6 408/4885SMN1; SMN2 1130/4885HPGD 1190/4885 |
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | HTR6 359/4885SMN1; SMN2 3949/4885HPGD 344/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | HTR6 1690/4885SMN1; SMN2 2836/4885HPGD 4822/4885 |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | HTR6 752/4885SMN1; SMN2 1897/4885HPGD 28/4885 |
| US-20100305088-A1 | INHIBITORS OF THE CHEMOKINE RECEPTOR CxCR3 | CXCR3, CXCR1, ACKR3 | HTR6 1418/4885SMN1; SMN2 4238/4885HPGD 1115/4885 |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | HTR6 1405/4885SMN1; SMN2 4808/4885HPGD 472/4885 |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | HTR6 4027/4885SMN1; SMN2 3689/4885HPGD 1630/4885 |
| US-20190315745-A1 | CDK4/6 INHIBITOR | CDK4, CDK6, CDK2 | HTR6 1052/4885SMN1; SMN2 2811/4885HPGD 1145/4885 |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | HTR6 158/4885SMN1; SMN2 4130/4885HPGD 1190/4885 |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | HTR6 569/4885SMN1; SMN2 1400/4885HPGD 3959/4885 |
| US-20110318393-A1 | Substituted Pyrazole Compounds | AURKA, AURKC, AURKB | HTR6 4370/4885SMN1; SMN2 3898/4885HPGD 3766/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | HTR6 1419/4885SMN1; SMN2 1005/4885HPGD 2068/4885 |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | HTR6 1373/4885SMN1; SMN2 483/4885HPGD 2959/4885 |
| US-12545670-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | KRAS, HRAS, NRAS | HTR6 919/4885SMN1; SMN2 4354/4885HPGD 3453/4885 |
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | STK17A, STK17B, HSD17B7 | HTR6 2718/4885SMN1; SMN2 4632/4885HPGD 1424/4885 |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | HTR6 3112/4885SMN1; SMN2 4761/4885HPGD 2786/4885 |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | HTR6 1660/4885SMN1; SMN2 4550/4885HPGD 3156/4885 |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | OXTR, AVPR2, AVPR1B | HTR6 439/4885SMN1; SMN2 3412/4885HPGD 162/4885 |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | OXTR, AVPR2, AVPR1B | HTR6 374/4885SMN1; SMN2 3923/4885HPGD 252/4885 |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | HTR2C, HTR4, HTR2A | HTR6 36/4885SMN1; SMN2 1602/4885HPGD 3157/4885 |
| US-20140296214-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HTR6 2416/4885SMN1; SMN2 4813/4885HPGD 838/4885 |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | BDKRB1, BDKRB2, BRS3 | HTR6 792/4885SMN1; SMN2 2940/4885HPGD 2320/4885 |
| US-20180093983-A1 | 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS | IDO1, IDO2, TPH1 | HTR6 23/4885SMN1; SMN2 1811/4885HPGD 241/4885 |
| US-20200031795-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | HTR6 1142/4885SMN1; SMN2 1746/4885HPGD 1377/4885 |
| US-20200048217-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | HTR6 1142/4885SMN1; SMN2 1746/4885HPGD 1377/4885 |
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | HTR6 3382/4885SMN1; SMN2 4622/4885HPGD 1508/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | HTR6 4048/4885SMN1; SMN2 1774/4885HPGD 1166/4885 |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HTR6 2321/4885SMN1; SMN2 4731/4885HPGD 1726/4885 |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | HTR6 3492/4885SMN1; SMN2 974/4885HPGD 2883/4885 |
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | HTR6 307/4885SMN1; SMN2 3278/4885HPGD 1059/4885 |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | HTR6 1591/4885SMN1; SMN2 3267/4885HPGD 3540/4885 |
| US-11351265-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | HTR6 4430/4885SMN1; SMN2 381/4885HPGD 4442/4885 |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HTR6 428/4885SMN1; SMN2 3995/4885HPGD 473/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | HTR6 1693/4885SMN1; SMN2 4856/4885HPGD 1767/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HTR6 4465/4885SMN1; SMN2 4512/4885HPGD 3394/4885 |
| US-20160376240-A1 | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use | MUSK, NTRK3, NTRK2 | HTR6 71/4885SMN1; SMN2 1107/4885HPGD 1913/4885 |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | HTR6 3720/4885SMN1; SMN2 3156/4885HPGD 1241/4885 |
| US-20160318904-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HTR6 2416/4885SMN1; SMN2 4813/4885HPGD 838/4885 |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MCL1, TP53, TOP2A | HTR6 3211/4885SMN1; SMN2 986/4885HPGD 1124/4885 |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | HTR6 103/4885SMN1; SMN2 4549/4885HPGD 195/4885 |
| US-10174024-B2 | 5H-pyrido[3,2-B]indole compounds as anticancer agents | IDO1, IDO2, TPH1 | HTR6 23/4885SMN1; SMN2 1811/4885HPGD 241/4885 |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | BET1, EP300, RBBP5 | HTR6 3883/4885SMN1; SMN2 2102/4885HPGD 1462/4885 |
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HTR6 491/4885SMN1; SMN2 4368/4885HPGD 387/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | HTR6 307/4885SMN1; SMN2 3278/4885HPGD 1059/4885 |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | HTR6 1229/4885SMN1; SMN2 45/4885HPGD 1360/4885 |
| US-20100222324-A1 | Substituted Indole Compounds | BDKRB1, BDKRB2, EDNRB | HTR6 103/4885SMN1; SMN2 3917/4885HPGD 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.